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Abstract—Hyperfibrinogenemia at the beginning of ischemic stroke is associated with poor outcome.
We hypothesized that the sustained increase of plasma fibrinogen during stroke predicts outcome ind-
ependently of baseline fibrinogen concentration. We included 266 patients with first-ever ischemic str-
oke in whom plasma fibrinogen level was measured on days 1, 7, and 14. The sustained fibrinogen’s
increase was defined as the persistent elevation of fibrinogen’s concentration on days 7 and 14 by at least
20 % compared to the level on day 1. The functional outcome on day 30 was assessed using modified
Rankin Scale (mRS). Favorable outcome was defined as mRS 0–1. The sustained increase of fibrinogen
was found in 17 % of patients. On multivariate logistic regression analysis adjusted for age, NIHSS
score, baseline fibrinogen >2.66 mmol/L, presence of infection, and hyperglycemia, the sustained fib-
rinogen’s level was associated with reduced chance of favorable outcome (OR: 0.17, 95 % CI: 0.06–
0.48, P<0.01).
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INTRODUCTION
Clinical studies have demonstrated that increased
level of inflammatory parameters related to acute phase
reaction such as interleukin-6 or C-reactive protein
(CRP) predicts unfavorable outcome in ischemic stroke
patients (reviewed in [1]). Fibrinogen belongs to acute
phase proteins. Hyperfibrinogenemia in acute cerebral
ischemia is associated with increased risk of death with-
in 1 year after stroke [2] and poor functional outcome
[3]. Elevated fibrinogen level predicts also unfavorable
prognosis in stroke patients treated with intravenous
thrombolysis [4, 5].
Cerebral ischemia triggers acute phase reaction,
and the blood concentration of inflammatory param-
eters could rise during brain infarction [1]. There is,
however, a significant interindividual variability in
inflammatory response after stroke [6–8]. Most of
the studies investigating the relationship between in-
flammatory parameters and stroke prognosis have
used baseline and/or discharge values of studied
markers and have not taken into account the kinetics
of these parameters during stroke.
Two major groups of factors determine elevated
levels of inflammatory parameters in stroke patients [9,
10]. The first group is related to pre-stroke conditions and
includes genetic factors and comorbidities associated with
subclinical inflammation (for example, diabetes mellitus,
obesity, and atherosclerosis). These factors determine the
level of inflammatory parameters at the beginning of stroke
and reflect mainly chronic pre-existing inflammation. The
second group includes factors related to acute phase reac-
tion. These factors are responsible for inflammatory pa-
rameters’ increase during stroke and reflect acute inflam-
mation. The impact of these two groups of factors on stroke
outcome could be different. We hypothesized that the
sustained increase of plasma fibrinogen during stroke,
even in patients with low baseline fibrinogen concentra-
tion, predicts outcome independently of baseline fibrino-
gen concentration.
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METHODS
We retrospectively analyzed the prospectively collect-
ed data on prognosis in stroke patients. The consecutive
patients with first-ever ischemic stroke admitted to our
stroke unit within 24 h after stroke onset were eligible for
the study. The patients were recruited to the study between
January 2011 and September 2012. The only exclusion
criterion was the lack of patient’s consent for participation
in the study. No patient was treated with intravenous
thrombolysis.
All patients underwent head CTscan within 24 h after
stroke onset. Stroke severity on admission was assessed
using National Institute of Health Stroke Scale (NIHSS).
Arterial hypertension was diagnosed when its pres-
ence was documented in medical records or when at least
two readings of blood pressure were ≥140mmHg (systolic)
and ≥90 mmHg (diastolic) after the acute phase of stroke.
The diagnosis of diabetes mellitus was made when (1) the
patient had the recognized diabetes mellitus before stroke
as written in medical records and/or took hypoglycemic
drugs before stroke; (2) fasting plasma glucose measured
on days 6–10 was ≥7.0 mmol/L or fasting plasma glucose
was 6.1–6.9 mmol/L and 2-h plasma glucose was
≥11.1 mmol/L after oral glucose tolerance test. A patient
was defined as a smoker if there was a history of cigarette
smoking during the last 5 years.
Plasma fibrinogen level was determined on days 1, 7,
and 14 using modified Clauss method (Dade Behring,
Marburg, Germany). Hyperfibrinogenemia was defined
as plasma concentration >3.5 g/L. We defined arbitrarily
the sustained increase of plasma fibrinogen as persistent
elevation of fibrinogen’s concentration on days 7 and 14 by
at least 20 % compared to the level on day 1. In addition,
the fibrinogen’s increase by at least 30%was considered in
statistical analysis.
The functional outcome at day 30 was determined
using modified Rankin Scale (mRS). The favorable out-
come was defined as mRS 0–1.
The study protocol was approved by the Bioethics
Committee of Jagiellonian University, and each participant
gave the informed consent.
The χ2 test was used to compare proportions and
Mann–Whitney’s test to compare continuous variables
between groups. Friedman’s ANOVA was used to
compare serial fibrinogen measurements. Values of less
than 0.05 were considerate to indicate statistical
significance. Logistic regression analysis was used to
assess if the sustained increase of fibrinogen is an
independent predictor of favorable outcome. Since the
baseline (day 1) fibrinogen level did not fulfil the
linearity assumption of an interval-dependent variable,
we divided the patients into two groups according to the
median value: those with low (≤2.66 mmol/L) and those
with high baseline fibrinogen (>2.66 mmol/L). Logistic
regression was also used to assess the independent
correlates of the sustained increase of fibrinogen. The
variables with P<0.10 on univariate analysis were
included in multivariate analysis. The calculations were
performed using the program STATISTICA for Windows
(version 10, Statsoft, Poland).
RESULTS
Three hundred thirty patients fulfilled the inclusion
criteria. Sixty one (18 %) of them was lost, because they
died within 14 days after stroke onset, did not agree to
participate, or there was a lack of important data (out-
come, fibrinogen measurements). The final cohort in-
cluded 266 patients (median age [IQ]: 70.0 [64–78],
47.7 % men). The lost patients did not differ significant-
ly from the final cohort in terms of age (median [IQ]: 75
[65–83] vs 70 [64–78], P=0.06) and NIHSS score on
admission (median [IQ]: 13 [8–21] vs 11.5 [8–16],
P=0.17); however, the lost patients had the higher plas-
ma fibrinogen on day 1 (median [IQ]: 2.9 [2.6–3.4] vs
2.7 [2.3–3.1], P<0.01).
The plasma fibrinogen levels are shown on Fig. 1.
Friedman’s ANOVA for the three groups (df=2) did not
reveal any significant difference (P=0.13). Wilcoxon’s
signed-rank test (without Bonferroni correction) demon-
strated the difference between fibrinogen on day 1 and
fibrinogen on day 7 (P=0.03).
The sustained increase of fibrinogen (e.g., fibrinogen
concentrations on days 7 and 14 higher by 20 % compared
to fibrinogen on day 1) was found in 45 patients (16.9 %).
The fibrinogen’s concentrations in patients with sustained
fibrinogen’s increase and patients without it are shown in
Fig. 2. Table 1 shows the characteristics of patients with
sustained fibrinogen’s increase and those without such an
increase. The patients with sustained fibrinogen’s increase
less often suffered from atrial fibrillation, had higher plas-
ma glucose on admission and triglyceride level, and lower
fibrinogen concentration on day 1. They also more fre-
quently had in-hospital pneumonia.
Multivariate logistic regression analysis including
variables that reached P<0.1 on univariate analysis (age,
NIHSS score, atrial fibrillation, plasma glucose on admis-
sion, triglycerides, fibrinogen on day 1, pneumonia)
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showed that higher NIHSS score (OR: 1.09, 95 % CI:
1.02–1.16, P<0.01), hypertriglyceridemia defined as tri-
glyceride >2.3 mmol/L (OR: 3.32, 95 % CI: 1.17–9.39,
P=0.02), and baseline fibrinogen >2.66mmol/L (OR: 0.07,
95 % CI: 0.02–0.19, P<0.01) were independently associ-
ated with sustained fibrinogen’s increase during stroke.
On univariate analysis, the sustained fibrinogen’s
increase ≥20% was associated with reduced chance of
Fig. 1. Plasma fibrinogen’s concentration during stroke. No significant change in fibrinogen’s concentration was found during observation period (P=0.13,
non-parametric ANOVA, df=2).
Fig. 2. Plasma fibrinogen’s concentration in patients with and in those without sustained fibrinogen’s increase. The data are shown as a median with inte-
rquartiles (the box) accompanied by the minimal and maximal values.
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favorable outcome (OR: 0.41, 95 % CI: 0.20–0.85,
P=0.01). Other variables significantly associated with
favorable outcome on univariate analysis were age (OR:
0.95, 95 % CI: 0.93–0.97, P<0.01), NIHSS score on
admission (OR: 0.75, 95 % CI: 0.69–0.80, P<0.01),
presence of infection including pneumonia and urinary
tract infections during hospitalization (OR: 0.39, 95 %
CI: 0.23–0.65, P<0.01), hyperglycemia defined as
fasting glycemia on day 1 >7.0 mmol/L (OR: 0.50,
95 % CI: 0.27–0.90, P=0.02), and baseline fibrinogen
>2.66 mmol/L (OR: 0.43, 95 % CI: 0.26–0.71, P<0.01).
On multivariate analysis, after adjustment for the
abovementioned confounders, fibrinogen’s increase
≥20% remained an independent predictor of favorable
outcome (OR: 0.17, 95 % CI: 0.06–0.48, P<0.01). Other
significant predictors of outcome were: age (OR: 0.95,
95 % CI: 0.91–0.98, P<0.01), NIHSS score (OR: 0.77,
95 % CI: 0.71–0.83, P<0.01), and baseline fibrinogen
>2.66 mmol/L (OR: 0.22, 95 % CI: 0.10–0.49, P<0.01).
The similar results of multivariate analysis were
obtained when fibrinogen’s increase ≥30 % was used
in the model (OR: 0.14, 95 % CI: 0.05–0.43, P<0.01).
DISCUSSION
In this study, we hypothesized that not only baseline
concentration of plasma fibrinogen but also its persistent
elevation during stroke has the negative effect on outcome.
We found that the sustained increase of fibrinogen level
during stroke is associated with reduced chance of favor-
able outcome and independent baseline fibrinogen level.
The elevated level of inflammatory markers such as
CRP or fibrinogen at the beginning of stroke may reflect the
burden of atherosclerosis and/or the presence of concomitant
risk factors (e.g., hypertension, diabetes mellitus, obesity)
[9]. In addition, the blood level of these markers could rise
during stroke as a part of the acute phase reaction [1]. There
is a significant interindividual variability in inflammatory
response after stroke. In one study where serum CRP was
Table 1. Characteristics of Stroke Patients with Sustained Fibrinogen’s Increase and those Without Sustained Fibrinogen’s Increase
Patients with sustained
fibrinogen’s increase (N=45)
Patients without sustained
fibrinogen’s increase (N=221)
P
Age, median (IQ) 68 (62–74) 71 (64–79) 0.09
Men, n (%) 23 (51.1) 104 (47.1) 0.62
Hypertension, n (%) 28 (62.2) 148 (67.0) 0.54
Diabetes mellitus, n (%) 13 (28.9) 44 (19.9) 0.18
Previous myocardial infarction, n (%) 3 (6.7) 23 (10.4) 0.44
Atrial fibrillation, n (%) 2 (4.4) 39 (17.6) 0.02
Smoking, n (%) 13 (28.9) 60 (27.1) 0.81
TIA prior to stroke, n (%) 5 (11.1) 16 (7.2) 0.38
NIHSS score on admission, median (IQ) 13 (10–18.5) 11 (8–16) 0.06
Systolic blood pressure on admission (mmHg), median (IQ) 160 (150–170) 160 (140–180) 0.42
Diastolic blood pressure on admission (mmHg), median (IQ) 90 (90–100) 90 (80–100) 0.86
Glucose on admission (mmol/L), median (IQ) 6.9 (5.8–9.4) 6.5 (5.4–7.8) 0.04
Fasting glucose (mmol/L), median (IQ) 6.0 (5.4–7.0) 5.9 (5.1–7.1) 0.40
Total cholesterol (mmol/L), median (IQ) 5.7 (4.6–6.7) 5.2 (4.5–6.3) 0.12
LDL-cholesterol (mmol/L), median (IQ) 3.5 (2.9–4.8) 3.4 (2.6–4.2) 0.32
HDL-cholesterol (mmol/L), median (IQ) 1.2 (1.1–1.6) 1.3 (1.1–1.5) 0.66
Triglyceride, (mmol/L), median (IQ) 1.5 (1.3–2.2) 1.3 (1.1–1.7) <0.01
WBC count (/μL), median (IQ) 8300 (6200–10,400) 8200 (6900–10,700) 0.83
Fibrinogen—day 1 (g/L), median (IQ) 2.2 (1.8–2.6) 2.8 (2.4–3.3) <0.01
Fibrinogen—day 7 (g/L), median (IQ) 3.5 (2.9–4.7) 2.8 (2.3–3.3) <0.01
Fibrinogen—day 14 (g/L), median (IQ) 3.4 (2.9–4.0) 2.7 (2.2–3.2) <0.01
Hyperfibrinogenemia on day 1, n (%) 1 (2.2) 41 (18.5) 0.01
Hyperfibrinogenemia on day 7, n (%) 21 (46.7) 42 (19.0) <0.01
Hyperfibrinogenemia on day 14, n (%) 19 (42.2) 36 (16.3) <0.01
In-hospital pneumonia, n (%) 10 (22.2) 25 (11.3) 0.048
Urinary tract infections, n (%) 14 (31.1) 94 (42.5) 0.15
mRS 0–1 at day 30, n (%) 12 (26.7) 103 (46.6) 0.01
IQ interquartiles, mRS modified Rankin Scale, NIHSS National Institute of Health Stroke Scale, TIA transient ischemic attack, WBC white blood cells
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measured within 24 h after stroke onset, within 48–72 h and
at hospital discharge, persistently normal values were seen
in 19.5 % of patients, increasing values in 6.3 %, decreasing
values in 28.1 %, and persistent elevation in 46.1 % [6]. In
another study, 38 % of ischemic stroke patients had normal
CRP levels on days 1 and 90, 40 % had elevated CRP on
both days, 14 % demonstrated an increase from normal to
elevated, and 8 % showed a decrease from elevated to
normal values [7]. In that study, in 28 % of patients, fibrin-
ogen level did not change by >50 mg/dL between days 1
and 90, 59 % of patients showed an increase, and 13 %
showed a decrease between both time points.
Although in our cohort plasma fibrinogen level rose
during the stroke, non-parametric ANOVA (Friedman’s
test) did not reveal the significant differences between
fibrinogen concentration measured on days 1, 7, and 14.
In some studies, fibrinogen level rose significantly during
stroke course [7, 11]; whereas, in other studies, no evidence
of time trend was seen [12] or fibrinogen concentration
increased gradually during serial measurement, but did not
reach significant level [3, 13].
The sustained elevation of fibrinogen level by 20%was
found in 17 % of our patients. Interestingly, only 2.2 % of
them had hyperfibrinogenemia on day 1. Of note, low fibrin-
ogen level on day 1 predicted the increase of this protein’s
concentration during stroke. More severe stroke and higher
triglyceride level were other predictors of sustained fibrino-
gen’s increase. Stroke severity is a major determinant of acute
phase reaction after stroke [1], and hypertriglyceridemia is
associated with systemic inflammation [14]. The higher fre-
quency of hypertriglyceridemia in patients without atrial
fibrillation compared to those with atrial fibrillation (13.9 %
vs 2.4 %, P=0.03) could explain the significant association
between atrial fibrillation and sustained fibrinogen’s increase
found on univariate but not on multivariate analysis.
The observational studies are not able to demonstrate
causality between increased level of inflammatory markers
including fibrinogen and poor outcome after stroke. The
interventional study with ancrod, the defibrinogenating
agent, showed that this drug starting within 6 h after
ischemic stroke symptom onset did not improve the out-
come despite the success to achieve rapid initial
defibrogenation and avoid prolonged hypofibrinogenemia
[15]. Although the lack of benefit after ancrod administra-
tion could be related to the side effects of the drug (in-
creased incidence of infections, renal failure, and intrace-
rebral bleeding), it may also suggest that elevated level of
fibrinogen is only the biomarker of prognosis, but not the
target for the treatment. If the elevation of fibrinogen level
is only epiphenomenon without direct effect on outcome, it
is important to recognize the mechanisms leading to the
increase of inflammatory molecules in blood during stroke,
because these mechanisms could also influence the out-
come and be a potential therapeutic target. On the other
hand, if increased fibrinogen level has a direct deleterious
effect on cerebral ischemia, it should be taken into consid-
eration that therapy that lowers its level should be not
limited to the first hours after stroke onset, but it needs to
be continued longer to prevent the increase of fibrinogen in
patients who had normal fibrinogen level on admission.
In conclusion, the sustained increase of fibrinogen dur-
ing stroke, also in patients with low fibrinogen level on day 1,
is associated with reduced chance of favorable outcome.
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